Main Article Content


2-Deoxy-D-Glucose with its long run history as a trialling anti-cancer agent has now approved for the management of moderate to severe corona positive patients in India. So far 218 clinical trials are going on in oncology using this drug as intervention or else as adjunct. 2-Fluro-Deoxy-D-Glucose an analogue of 2-Deoxy-D-Glucose is also being used as a radiotracer. Glucose is the source of energy for all cells in human body. As an anti-glycolytic agent, 2-Deoxy-D-Glucose put the high glucose utilizing neoplastic cells at starvation and leads to autophagy. It can also destroy high glucose demanding healthy cell like neurons is also a matter of concern. The same anti-glycolytic property is responsible for halting the pathogenesis of Severe Acute Respiratory Syndrome Corona Virus-2.It is noteworthy that the drug can also reduce oxygen dependence in active corona patients. This review collectively examines the anti-cancer and anti-viral nature of 2-Deoxy-D-Glucose. It epitomises the pharmacodynamic potential of the drug in both oncology and virology. Listing out clinical trials conducted so far using this drug as an intervention in both oncology and virology and shedding light towards the adverse effects of this drug are also important objectives.


COVID-19 2-Deoxy-D-Glucose SARS-CoV-2 Cancer Clinical trials Adverse effects

Article Details